Chardan Capital Maintains Buy on Krystal Biotech, Raises Price Target to $148
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $133 to $148.
May 22, 2023 | 11:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating on Krystal Biotech and raises the price target from $133 to $148.
Chardan Capital's Buy rating and increased price target for Krystal Biotech (KRYS) indicate a positive outlook for the stock. The raised target suggests that the analyst believes the stock has potential for further growth, which could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100